Targeting cytokines to inflammation sites

To increase the half-life of a cytokine and target its activation specifically to disease sites, we have engineered a latent cytokine using the latency-associated protein (LAP) of transforming growth factor-β1 (TGF-β1) fused via a matrix metalloproteinase (MMP) cleavage site to interferon (IFN)-β at either its N or C terminus. The configuration LAP-MMP-IFN-β resembles native TGF-β and lacks biological activity until cleaved by MMPs, whereas the configuration IFN-β-MMP-LAP is active. LAP provides for a disulfide-linked shell hindering interaction of the cytokine with its cellular receptors, conferring a very long half-life of 55 h in vivo. Mutations of the disulfide bonds in LAP abolish this latency. Samples of cerebrospinal fluid (CSF) or synovial fluid from patients with inflammatory diseases specifically activate the latent cytokine, whereas serum samples do not. Intramuscular injection in arthritic mice of plasmid DNA encoding these constructs demonstrated a greater therapeutic effect of the latent as compared to the active forms.

[1]  S. Schultz-Cherry,et al.  The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. , 1994, The Journal of biological chemistry.

[2]  V. Perry,et al.  Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke , 1997, Neuropathology and applied neurobiology.

[3]  M. Schuler,et al.  Interleukins , 1994, Drugs.

[4]  F. Cosset,et al.  A gene delivery system activatable by disease-associated matrix metalloproteinases. , 1997, Human gene therapy.

[5]  Y. Itoh,et al.  Steps Involved in Activation of the Pro-matrix Metalloproteinase 9 (Progelatinase B)-Tissue Inhibitor of Metalloproteinases-1 Complex by 4-Aminophenylmercuric Acetate and Proteinases (*) , 1995, The Journal of Biological Chemistry.

[6]  M. Satoh,et al.  Stable production of recombinant pro-urokinase by human lymphoblastoid Namalwa KJM-1 cells: Host-cell dependency of the expressed-protein stability , 2004, Cytotechnology.

[7]  T. Waldmann,et al.  The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. , 1999, Annual review of immunology.

[8]  S Goelz,et al.  The crystal structure of human interferon beta at 2.2-A resolution. , 1997 .

[9]  W. Anderson,et al.  Capture and expansion of bone marrow-derived mesenchymal progenitor cells with a transforming growth factor-beta1-von Willebrand's factor fusion protein for retrovirus-mediated delivery of coagulation factor IX. , 1997, Human gene therapy.

[10]  J. Weidner,et al.  Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis. , 1997, Osteoarthritis and cartilage.

[11]  J. Becker,et al.  Immunocytokines: a promising approach to cancer immunotherapy. , 1998, Pharmacology & therapeutics.

[12]  Y. Chernajovsky,et al.  Pathogenic lymphoid cells engineered to express TGF β1 ameliorate disease in a collagen-induced arthritis model , 1997, Gene Therapy.

[13]  D. Hupe,et al.  Reconstructed 19 kDa catalytic domain of gelatinase A is an active proteinase. , 1995, Biochemistry.

[14]  D. Rifkin,et al.  Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells , 1993, The Journal of cell biology.

[15]  A. Manning,et al.  AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. , 1998, Autoimmunity.

[16]  R. Derynck.  TGF-β-receptor-mediated signaling , 1994 .

[17]  M. Sporn,et al.  Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. , 1990, The Journal of clinical investigation.

[18]  A. Ison,et al.  Monitoring proteolysis of recombinant human interferon-γ during batch culture of Chinese hamster ovary cells , 2004, Cytotechnology.

[19]  D. Rifkin,et al.  Latent Transforming Growth Factor-β Binding Protein Domains Involved in Activation and Transglutaminase-dependent Cross-Linking of Latent Transforming Growth Factor-β , 1997, The Journal of cell biology.

[20]  M. Sporn,et al.  Recombinant TGF-β1 is Synthesized as a Two-Component Latent Complex that Shares Some Structural Features with the Native Platelet Latent TGF-β1 Complex , 1989 .

[21]  J. Taipale,et al.  Latent transforming growth factor-beta binding proteins (LTBPs)--structural extracellular matrix proteins for targeting TGF-beta action. , 1999, Cytokine & growth factor reviews.

[22]  Y. Chernajovsky,et al.  Efficient constitutive production of human fibroblast interferon by hamster cells transformed with the IFN-beta 1 gene fused to an SV40 early promoter. , 1984, DNA.

[23]  H. Shimada,et al.  Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. , 1992, Cancer research.

[24]  K. Margolin.  Interleukin-2 in the treatment of renal cancer. , 2000, Seminars in oncology.

[25]  G. Opdenakker,et al.  Production and characterization of recombinant active mouse gelatinase B from eukaryotic cells and in vivo effects after intravenous administration. , 1997, European journal of biochemistry.

[26]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[27]  J. V. van Meurs,et al.  Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity. , 1999, Arthritis and rheumatism.

[28]  Jussi Taipale,et al.  Growth factors in the extracellular matrix , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  D. Baker,et al.  Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. , 2001, The Journal of pharmacology and experimental therapeutics.

[30]  M. Feldmann,et al.  Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. , 1998, Journal of immunology.

[31]  R. Hynes,et al.  Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo , 1998, Cell.

[32]  A. Brunner,et al.  Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins. , 1989, The Journal of biological chemistry.

[33]  D. Rifkin,et al.  Interactions between growth factors and integrins: latent forms of transforming growth factor-beta are ligands for the integrin alphavbeta1. , 1998, Molecular biology of the cell.

[34]  M. Nimni,et al.  Refolding of a recombinant collagen-targeted TGF-beta2 fusion protein expressed in Escherichia coli. , 1997, Protein expression and purification.

[35]  J. Belaiche,et al.  Increased production of matrix metalloproteinase‐3 and tissue inhibitor of metalloproteinase‐1 by inflamed mucosa in inflammatory bowel disease , 2000, Clinical and experimental immunology.

[36]  L. Madisen,et al.  Site-directed mutagenesis of glycosylation sites in the transforming growth factor-beta 1 (TGF beta 1) and TGF beta 2 (414) precursors and of cysteine residues within mature TGF beta 1: effects on secretion and bioactivity. , 1992, Molecular endocrinology.

[37]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P. Libby,et al.  The interface of atherosclerosis and thrombosis: basic mechanisms , 1998, Vascular medicine.

[39]  L. Kappos,et al.  Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. , 1998, Brain : a journal of neurology.

[40]  J. Taipale,et al.  Association of the small latent transforming growth factor‐beta with an eight cysteine repeat of its binding protein LTBP‐1. , 1996, The EMBO journal.

[41]  C. J. Taylor,et al.  Matrix metalloproteinase levels are elevated in inflammatory bowel disease. , 1999, Gastroenterology.

[42]  A. Annenkov,et al.  Soluble complement receptor 1 (CD35) delivered by retrovirally infected syngeneic cells or by naked DNA injection prevents the progression of collagen-induced arthritis. , 2000, Arthritis and rheumatism.

[43]  G. Fields,et al.  Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. , 1996, Biopolymers.

[44]  Yoram Vodovotz,et al.  Regulation of transforming growth factor b1 by nitric oxide , 1999 .

[45]  Y. Chernajovsky,et al.  Cloning and expression of murine IFNβ and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis , 1998, Gene Therapy.

[46]  S. Hauschka,et al.  Identification of a myocyte nuclear factor that binds to the muscle-specific enhancer of the mouse muscle creatine kinase gene , 1989, Molecular and cellular biology.

[47]  M. Sporn,et al.  Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[48]  E. Kubota,et al.  Interleukin 1 beta and stromelysin (MMP3) activity of synovial fluid as possible markers of osteoarthritis in the temporomandibular joint. , 1997, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[49]  I. Massova,et al.  Structural Insights into the Catalytic Domains of Human Matrix Metalloprotease-2 and Human Matrix Metalloprotease-9: Implications for Substrate Specificities , 1997 .

[50]  Richard O. Williams,et al.  Amelioration of collagen-induced arthritis and suppression of interferon-?, interleukin-12, and tumor necrosis factor ? production by interferon-? gene therapy , 1999 .

[51]  J U Gutterman,et al.  Cytokine therapeutics: lessons from interferon alpha. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. Gołąb,et al.  Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review). , 1999, International journal of molecular medicine.

[53]  N. Khalil.  TGF-β: from latent to active , 1999 .

[54]  D. Rifkin,et al.  Interactions between Growth Factors and Integrins: Latent Forms of Transforming Growth Factor-β Are Ligands for the Integrin αvβ1 , 1998 .

[55]  T. Taniguchi.  Regulation of cytokine gene expression. , 1988, Annual review of immunology.